Anthony Tennyson
Person
Anthony Tennyson is the Chief Executive Officer of Solvonis Therapeutics plc, a CNS-focused company listed on the London Stock Exchange under the ticker SVNS. He is known for leading the company as it develops its therapeutics business.
What Anthony Tennyson has said on podcasts
11 statements
EU trial data could improve SVN001’s probability of EU marketing approval.
“what our hope would be that if we have EU data in the trial, it would increase the probability of an accepted marketing authorization or marketing approval in certain EU countries in due course.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 3:59
Funding enables SVN002 bridge completion and FDA engagement for Phase 2B support.
“what this money enables us to do is to complete that process and then engage with the FDA, present the data to them and hopefully gain their support for a phase two program, but ideally a phase two B program.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 4:57
Successful SVN015 work could position Solvonis to seek NIDA clinical-development funding.
“if that's successful, then what we would hope is we'd be able to be well positioned to apply for grant funding from NIDA to bring that program forward into clinic and into humans.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 5:47
Adding EU data would significantly increase SVN001’s strategic optionality.
“by potentially adding in EU data, we increase the, let's just call it optionality for that program, I believe, significantly.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 6:38
Spravato is forecast to reach approximately a $2 billion run rate for J&J.
“J&J Spravato is currently forecast, I think, to be about a $2 billion run rate business for J&J”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 7:24
Solvonis hopes to complete SVN002 FDA-related work before year-end.
“we would hope to have all of that done before the end of the year.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 12:14
SVN015’s next tests, studies and results should occur during the rest of the year.
“And that should be through the course of the remainder of this year.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 12:35
Tennyson believes Solvonis has a very good business and plan.
“We are, we have a, what I believe to be a very good business. with a very good plan.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 14:05
Solvonis’s team should execute, create value and communicate progress.
“What I and the team now need to do is put our head down and execute, create value and communicate that to the street”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 14:24
New York-listed peers receive materially higher valuations than Solvonis’s London listing.
“when you look at our peers, listed in New York, where there is greater demand for these stories. There's a greater availability of capital for these stories. The valuations are of an order of magnitude different.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 15:08
Solvonis should use raised capital prudently to execute and communicate potential value creation.
“We need to use that capital judiciously. to execute the business plan and to communicate out to investors so that current investors and potential new investors understand the value that we have the potential to create.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 15:33
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
